The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel discussed:
- When is the right time to get acquired?
- What is the survival rate of c-suite after an acquisition?
- Why is an acquisition better than a collaboration?
- What are the key issues in the due diligence process that can hurt the value of the deal?
- How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
- What types of steps can be taken to prepare a forecast that drives value negotiations
- How can this analysis be leverage in negotiating a collaborative or co-partner agreement
Presenters included:
- Todd Boudreau, Senior Counsel, Private Equity & Venture Capital Practice, Foley
- Dr. Ton Bunt, Senior Advisor, JSB Partners LP
- Sven Riethmueller, Of Counsel, Private Equity & Venture Capital, Foley
- David Schechner, Managing Director, Canaccord Adams
- Shane Senior, Managing Director, Crosstree Capital Partners Inc.
Related Insights
24 April 2025
Foley Viewpoints
Prop 65: Changes to Short-Form Warnings Will Cause Long-Term Impacts
The California Office of Environmental Health Hazard Assessment recently amended its regulations concerning requirements for consumer product warnings to qualify for “safe harbor” protection from enforcement actions brought under the Safe Drinking Water and Toxic Enforcement Act of 1986, commonly known as Proposition 65.
24 April 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Customs Enforcement and False Claims Act Risks (Part II)
As detailed in Part I of our three-part series on Minimizing Customs Enforcement and False Claims Act Risks, the combination of the new high-tariff environment, the heightened ability of Customs (and the general public) to data mine, and the Department of Justice’s stated focus on using the False Claims Act substantially increases import-related risks.
24 July 2025
Events
ACI's Inaugural Summit on GLP-1 Law & Policy
Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking in American Conference Institute’s Inaugural Summit on GLP-1 Law & Policy on July 24.